William Sandborn

Appearances

EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
Date
May 21, 2024
BACKGROUND: VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis (UC)…
Presenter
Bruce Sands
Speakers
Remo Panaccione
Geert D’Haens
Stefan Schreiber
Aaron DuVall
Jaroslaw Kierkus
Snehal Naik
Kye Gilder
Chohee Yun
William Sandborn
Michal Walczak
Séverine Vermeire
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
David Rubin
Laurent Peyrin-Biroulet
Silvio Danese